Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Exclusion Criteria

• •The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication;
• •The patients suffered from organ transplant
• •The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies;
• •The patients with active bleeding or new thrombotic disease, who are taking anticoagulant drugs or with a history of bleeding tendencies;
• •The patients suffered before surgery less than four weeks, or after less than six weeks;
• •The patients with major vascular invasion;
• •The patients with abnormal liver function (total bilirubin\> 1.5 times the normal value, ALT / AST\> 2.5 times normal), abnormal renal function (serum creatinine\> 1.5 times normal), blood abnormalities (absolute neutrophil count \<1.5 × 109 / L, platelets \<80 × 109 / L, hemoglobin \<90g /L) ;
• •The patients with moderate to severe proteinuria;
• •Severe hypertension,BP≥160/100mmHg;
• •The patients with mentally ill / unable to obtain informed consent;
• •The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results;
• •The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects;
• •Clinical and laboratory support brain metastases;
• •The patients with a history of allergy to test drug;
• •The patients not suitable to participate in the investigator judged by researchers.